{"id":"weekly-cisplatin","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Nephrotoxicity"},{"rate":"5-15","effect":"Ototoxicity"},{"rate":"70-90","effect":"Nausea and vomiting"},{"rate":"25-75","effect":"Myelosuppression"},{"rate":"10-20","effect":"Peripheral neuropathy"},{"rate":"20-30","effect":"Anemia"},{"rate":"25-35","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Cisplatin is a DNA-damaging chemotherapy drug that binds to DNA and forms intrastrand and interstrand crosslinks, preventing DNA replication and transcription. This leads to cell cycle arrest and programmed cell death (apoptosis) in rapidly dividing cancer cells. The weekly dosing schedule is designed to improve tolerability compared to standard higher-dose cisplatin regimens while maintaining efficacy.","oneSentence":"Weekly cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit cancer cell replication and induce apoptosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:02.235Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various solid tumors (specific indications dependent on phase 3 trial design)"}]},"trialDetails":[{"nctId":"NCT03811015","phase":"PHASE3","title":"Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-16","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":636},{"nctId":"NCT07276360","phase":"PHASE2","title":"Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda","status":"RECRUITING","sponsor":"Uganda Cancer Institute","startDate":"2026-03-11","conditions":"Cervical Cancer, Cervix Cancer, Cervical Adenocarcinoma","enrollment":278},{"nctId":"NCT06770582","phase":"PHASE2","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-03","conditions":"Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8","enrollment":160},{"nctId":"NCT05172245","phase":"PHASE1","title":"Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-09-19","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT07195734","phase":"PHASE2","title":"Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-09","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":180},{"nctId":"NCT03952585","phase":"PHASE2, PHASE3","title":"De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-09","conditions":"Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":384},{"nctId":"NCT07061977","phase":"PHASE3","title":"Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-05","conditions":"Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma","enrollment":336},{"nctId":"NCT07497607","phase":"PHASE2","title":"Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sara Medek","startDate":"2026-06-01","conditions":"Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":31},{"nctId":"NCT03775265","phase":"PHASE3","title":"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-03","conditions":"Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8","enrollment":475},{"nctId":"NCT06323460","phase":"PHASE2","title":"Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-03-21","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma","enrollment":45},{"nctId":"NCT03410615","phase":"PHASE2","title":"Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-05-28","conditions":"Oropharyngeal Squamous Cell Carcinoma","enrollment":129},{"nctId":"NCT03493425","phase":"PHASE2","title":"Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-03-12","conditions":"Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7","enrollment":82},{"nctId":"NCT06792786","phase":"NA","title":"A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring","status":"RECRUITING","sponsor":"The Central Hospital of Lishui City","startDate":"2024-12-10","conditions":"Esophageal Cancer, ctDNA","enrollment":30},{"nctId":"NCT02734537","phase":"PHASE2","title":"Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2016-11-23","conditions":"Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma","enrollment":189},{"nctId":"NCT04658862","phase":"PHASE3","title":"A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-12-07","conditions":"Urinary Bladder Neoplasms","enrollment":518},{"nctId":"NCT04430699","phase":"PHASE2","title":"Cisplatin+Pembrolizumab+RT in Vulvar Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-29","conditions":"Vulvar Cancer, Vulvar Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT01612351","phase":"PHASE2","title":"Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2012-06","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck","enrollment":40},{"nctId":"NCT01810913","phase":"PHASE2, PHASE3","title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-03-22","conditions":"Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7","enrollment":613},{"nctId":"NCT05521997","phase":"PHASE2","title":"Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-07-31","conditions":"Advanced Cervical Carcinoma, Cervical Cancer, Cervix Cancer","enrollment":42},{"nctId":"NCT01616875","phase":"PHASE2","title":"Bristol Bladder Trial","status":"COMPLETED","sponsor":"University Hospitals Bristol and Weston NHS Foundation Trust","startDate":"2012-07-25","conditions":"Infiltrating Bladder Urothelial Carcinoma","enrollment":28},{"nctId":"NCT04502407","phase":"PHASE2","title":"Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2021-02-16","conditions":"HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT05050162","phase":"PHASE2, PHASE3","title":"Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer","status":"SUSPENDED","sponsor":"NRG Oncology","startDate":"2022-02-01","conditions":"Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma","enrollment":1714},{"nctId":"NCT07445048","phase":"PHASE3","title":"Postoperative Radiotherapy Combined With Nimotuzumab Followed by Bemcentinib in High-Risk Patients With Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2026-03-05","conditions":"Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer, Postoperative Adjuvant Treatment","enrollment":370},{"nctId":"NCT07026474","phase":"PHASE3","title":"Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC","status":"RECRUITING","sponsor":"Universität des Saarlandes","startDate":"2025-10-30","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":214},{"nctId":"NCT02031250","phase":"PHASE2","title":"Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2014-02","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":106},{"nctId":"NCT07441681","phase":"PHASE3","title":"Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin","status":"NOT_YET_RECRUITING","sponsor":"NRG Oncology","startDate":"2027-01-06","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":454},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT07039162","phase":"PHASE2","title":"Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Ming-Yu Lien","startDate":"2025-09-26","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer","enrollment":45},{"nctId":"NCT07439497","phase":"PHASE2","title":"Definitive Hypofractionated Intensity-modulated Radiation Theraphy With Concurrent Chemotherapy in Cervical Cancer","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-12-09","conditions":"Cervical Cancer","enrollment":34},{"nctId":"NCT07435311","phase":"PHASE1","title":"A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2020-06-15","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":118},{"nctId":"NCT07435324","phase":"PHASE3","title":"A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm","startDate":"2024-08-08","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":161},{"nctId":"NCT03256916","phase":"PHASE3","title":"Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix","status":"COMPLETED","sponsor":"Tata Memorial Hospital","startDate":"2018-01-16","conditions":"Carcinoma Cervix,Stage III","enrollment":348},{"nctId":"NCT03174275","phase":"PHASE2","title":"Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2017-12-19","conditions":"Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer","enrollment":39},{"nctId":"NCT04221945","phase":"PHASE3","title":"Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-12","conditions":"Uterine Cervical Neoplasms","enrollment":1060},{"nctId":"NCT05386550","phase":"PHASE3","title":"Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-10-06","conditions":"Head and Neck Cancer","enrollment":166},{"nctId":"NCT05268614","phase":"PHASE2","title":"Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"University of Florida","startDate":"2022-05-16","conditions":"Oropharyngeal Squamous Cell Carcinoma","enrollment":250},{"nctId":"NCT03822897","phase":"PHASE2","title":"De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2019-06-28","conditions":"Oropharyngeal Cancer","enrollment":103},{"nctId":"NCT07415681","phase":"PHASE2","title":"GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries","status":"NOT_YET_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2026-03","conditions":"Gynaecologic Cancer, Cervical Cancer, Radiation Therapy","enrollment":116},{"nctId":"NCT07008833","phase":"NA","title":"Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Brazilian Clinical Research Institute","startDate":"2026-06","conditions":"Muscle Invasive Bladder Cancer","enrollment":336},{"nctId":"NCT06592599","phase":"PHASE2","title":"Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-09-03","conditions":"Nasopharyngeal Carcinoma","enrollment":24},{"nctId":"NCT07392580","phase":"PHASE2","title":"Intralesional Chemotherapy (IC): Cisplatin + Epinephrine","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-04-01","conditions":"Laryngeal Squamous Cell Carcinoma","enrollment":20},{"nctId":"NCT03258554","phase":"PHASE2, PHASE3","title":"Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-04-03","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma","enrollment":196},{"nctId":"NCT05139095","phase":"PHASE2","title":"Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-01-27","conditions":"Gestational Trophoblastic Neoplasia","enrollment":70},{"nctId":"NCT07097142","phase":"PHASE3","title":"Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2026-05-11","conditions":"Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8","enrollment":486},{"nctId":"NCT06532279","phase":"PHASE2","title":"Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2024-12-16","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":98},{"nctId":"NCT06484491","phase":"NA","title":"IMPT Dose Escalation for NSCLC (HyDose)","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2025-09-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":87},{"nctId":"NCT05502237","phase":"PHASE3","title":"Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-10-12","conditions":"Non-small Cell Lung Cancer","enrollment":1021},{"nctId":"NCT07214987","phase":"PHASE2","title":"PDT For Induction Therapy For Head And Neck Cancer","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-09","conditions":"Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":26},{"nctId":"NCT05366166","phase":"PHASE2","title":"Pembrolizumab Plus Olaparib in LA-HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2022-09-02","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":45},{"nctId":"NCT07368985","phase":"PHASE2","title":"Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer","status":"NOT_YET_RECRUITING","sponsor":"Prof. Dr. Remi A. Nout","startDate":"2026-03","conditions":"Cervical Cancer by FIGO Stage 2018, Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2, Adenocarcinoma or Adeno-squamous Carcinoma Stage IB3-IIIC2","enrollment":87},{"nctId":"NCT03323463","phase":"PHASE2","title":"Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-10-16","conditions":"HPV-Associated Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Neck","enrollment":316},{"nctId":"NCT03869190","phase":"PHASE1, PHASE2","title":"Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-06-01","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":272},{"nctId":"NCT04630730","phase":"PHASE2","title":"Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2022-06-24","conditions":"Bladder Cancer","enrollment":46},{"nctId":"NCT07343531","phase":"NA","title":"A Study Of Moderately Hypo-Fractionated External-beam Radiotherapy With Concurrent Chemotherapy and High Dose Rate Brachytherapy In Cervical Cancer","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-07-01","conditions":"Cervical Carcinoma Stage III, Cervical Carcinoma Stage IIB, Cervical Carcinoma Stage II","enrollment":30},{"nctId":"NCT04229459","phase":"PHASE2","title":"Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baruch Brenner","startDate":"2020-02-16","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":12},{"nctId":"NCT07340489","phase":"PHASE2","title":"Serplulimab for Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-03","conditions":"Cervical Cancer","enrollment":216},{"nctId":"NCT03267498","phase":"PHASE2","title":"Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)","status":"COMPLETED","sponsor":"Sue Yom","startDate":"2018-02-14","conditions":"Nasopharyngeal Carcinoma","enrollment":40},{"nctId":"NCT01302834","phase":"PHASE3","title":"Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2011-06","conditions":"Head and Neck Cancer, Precancerous Condition","enrollment":987},{"nctId":"NCT01025089","phase":"PHASE2","title":"Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2009-12","conditions":"Thymoma, Thymic Carcinoma, Clinical Masaoka Stage II to IVA","enrollment":18},{"nctId":"NCT07320690","phase":"PHASE3","title":"De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2026-01-01","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":356},{"nctId":"NCT06727617","phase":"PHASE2","title":"Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-11-19","conditions":"Cervical Cancers","enrollment":134},{"nctId":"NCT03215719","phase":"PHASE2","title":"Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2017-10-18","conditions":"Oropharyngeal Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":120},{"nctId":"NCT06416696","phase":"PHASE2","title":"Toripalimab for High-risk Locally Advanced Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-01-09","conditions":"Cervical Cancers","enrollment":57},{"nctId":"NCT00980954","phase":"PHASE3","title":"Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-09","conditions":"Cervical Cancer","enrollment":236},{"nctId":"NCT04124198","phase":"NA","title":"Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Christian von Buchwald","startDate":"2019-03-01","conditions":"Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, Carcinoma, Squamous Cell","enrollment":138},{"nctId":"NCT05494190","phase":"NA","title":"The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2022-11-01","conditions":"Hypopharyngeal Carcinoma","enrollment":111},{"nctId":"NCT06331468","phase":"PHASE2","title":"Hypofractionated Radiochemotherapy","status":"RECRUITING","sponsor":"Denise Fabian","startDate":"2025-06-26","conditions":"Uterine Cervix Cancer","enrollment":20},{"nctId":"NCT03643133","phase":"PHASE2","title":"Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2018-10-23","conditions":"Osteosarcoma","enrollment":60},{"nctId":"NCT01154920","phase":"PHASE2","title":"Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-07-09","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":128},{"nctId":"NCT06866951","phase":"PHASE2, PHASE3","title":"A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial","status":"WITHDRAWN","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-03-01","conditions":"Cervical Cancers","enrollment":""},{"nctId":"NCT04580446","phase":"PHASE1","title":"HYHOPE: De-intensified Hypofractionated Radiation Therapy for HPV-associated Oropharynx Cancer","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2020-12-03","conditions":"Human Papillomavirus-Related Carcinoma, Oropharyngeal Cancer","enrollment":24},{"nctId":"NCT02567422","phase":"PHASE1","title":"Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-17","conditions":"Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7","enrollment":43},{"nctId":"NCT02066220","phase":"PHASE2, PHASE3","title":"International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2014-06","conditions":"Brain Tumors","enrollment":360},{"nctId":"NCT07261592","phase":"PHASE1, PHASE2","title":"Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2025-12-01","conditions":"Bladder Cancer, Histone Deacetylase Inhibitor, Entinostat","enrollment":29},{"nctId":"NCT03358472","phase":"PHASE3","title":"Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-12-01","conditions":"Head and Neck Cancer","enrollment":89},{"nctId":"NCT06846450","phase":"PHASE3","title":"Phase 3 Trial Comparing IMRT or IMPT Plus CIRT for Patients With NPC","status":"RECRUITING","sponsor":"Lin Kong, MD","startDate":"2025-04-01","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":470},{"nctId":"NCT05462951","phase":"","title":"Clinical Trial of Molecular Biomarkers in Women With Uterine Cervix Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Denise Fabian","startDate":"2023-01-03","conditions":"Uterine Cervix Cancer","enrollment":19},{"nctId":"NCT07248670","phase":"PHASE3","title":"Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2025-10-04","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":252},{"nctId":"NCT07249021","phase":"","title":"This is a Multicentre International Study Evaluating CT-based IGABT With / Without Either TRUS During BT/Pre BT MR as Per IBS-GECESTRO-ABS Recommendations for Target contouring-as an Alternative to MRIGABT for Cervical Cancer From Implementation Perspectives Under EMBRACE-III:TRIPLET IMPACT Study.","status":"NOT_YET_RECRUITING","sponsor":"Homi Bhabha Cancer Hospital & Research Centre","startDate":"2025-11","conditions":"Locally Advanced Cervical Cancer, Brachytherapy, CT","enrollment":1200},{"nctId":"NCT07248696","phase":"NA","title":"Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2025-10-04","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":32},{"nctId":"NCT03132532","phase":"PHASE2","title":"Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-07-31","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":20},{"nctId":"NCT04595565","phase":"PHASE3","title":"Sacituzumab Govitecan in Primary HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GBG Forschungs GmbH","startDate":"2020-10-28","conditions":"HER2-negative Breast Cancer, Triple Negative Breast Cancer","enrollment":1332},{"nctId":"NCT07244965","phase":"PHASE2","title":"Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-12-01","conditions":"LOCALLY ADVANCED CERVICAL CANCERS","enrollment":42},{"nctId":"NCT00957411","phase":"PHASE2","title":"Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage IB, Stage II, or Stage IIIB Cervical Cancer","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2009-03","conditions":"Cervical Cancer","enrollment":76},{"nctId":"NCT06706401","phase":"PHASE3","title":"Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2025-02-20","conditions":"Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer","enrollment":460},{"nctId":"NCT06139419","phase":"PHASE2","title":"The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-07-25","conditions":"Non-small Cell Lung Cancer","enrollment":114},{"nctId":"NCT07086469","phase":"PHASE2","title":"Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-20","conditions":"Toripalimab, Surufatinib, Neoadjuvant Immunochemotherapy","enrollment":69},{"nctId":"NCT06912074","phase":"PHASE2","title":"Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-05","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":134},{"nctId":"NCT02595879","phase":"PHASE1","title":"Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-09-18","conditions":"Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma, Advanced Cervical Squamous Cell Carcinoma","enrollment":21},{"nctId":"NCT06445114","phase":"PHASE2","title":"Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer","status":"RECRUITING","sponsor":"Zachary Zumsteg","startDate":"2025-05-12","conditions":"Oropharyngeal Cancer, Carcinoma","enrollment":50},{"nctId":"NCT04169763","phase":"PHASE1","title":"Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-07","conditions":"Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8","enrollment":25},{"nctId":"NCT02994069","phase":"PHASE2","title":"Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Susanne Arnold","startDate":"2017-04-11","conditions":"Carcinoma, Squamous Cell, Head and Neck Cancer","enrollment":80},{"nctId":"NCT04580771","phase":"PHASE2","title":"A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-10-14","conditions":"Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB3 Cervical Cancer FIGO 2018, Stage II Cervical Cancer FIGO 2018","enrollment":22},{"nctId":"NCT02254278","phase":"PHASE2","title":"Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2014-10","conditions":"Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma","enrollment":316},{"nctId":"NCT03564691","phase":"PHASE1","title":"Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-11","conditions":"Neoplasms","enrollment":470},{"nctId":"NCT04442022","phase":"PHASE2, PHASE3","title":"A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-09-03","conditions":"Relapsed/Refractory Diffuse Large B-cell Lymphoma","enrollment":501},{"nctId":"NCT01982448","phase":"PHASE2","title":"Cisplatin vs Paclitaxel for Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-04","conditions":"Triple Negative Breast Cancer","enrollment":147},{"nctId":"NCT06056310","phase":"PHASE1","title":"Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2024-01-18","conditions":"Head and Neck Cancer","enrollment":18},{"nctId":"NCT05020457","phase":"PHASE2","title":"SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2021-12-07","conditions":"Non Small Cell Lung Cancer","enrollment":69},{"nctId":"NCT01326468","phase":"NA","title":"Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-12-08","conditions":"Head and Neck Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":923,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cisplatin"],"phase":"phase_3","status":"active","brandName":"weekly cisplatin","genericName":"weekly cisplatin","companyName":"Korea Cancer Center Hospital","companyId":"korea-cancer-center-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Weekly cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit cancer cell replication and induce apoptosis. Used for Various solid tumors (specific indications dependent on phase 3 trial design).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}